Gen­mab puts down $54M for im­munother­a­py col­lab­o­ra­tion — ready to spend mil­lions more

Af­ter fill­ing its pipeline with Big Phar­ma-part­nered an­ti­body ther­a­peu­tics, J&J dar­ling Gen­mab has turned to a fel­low Eu­ro­pean biotech for its lat­est for­ay in­to can­cer im­munother­a­pies.

Copen­hagen-based Gen­mab is pay­ing $54 mil­lion for three tar­gets iden­ti­fied by Im­mat­ics’ Xpres­i­dent plat­form, as well as ac­cess to its T cell re­cep­tor dis­cov­ery and en­gi­neer­ing plat­form. Im­mat­ics — which is head­quar­tered in Tue­bin­gen, Ger­many and runs a sub­sidiary in Hous­ton — is al­so in for $550 mil­lion in mile­stone pay­ments and a co-pro­mo­tion op­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER